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Abstract
Background: To identify potential therapeutic target in clear cell renal cell carcinoma (ccRCC), we performed a
transcriptome analysis. Our analysis showed that fatty acid binding protein 7 (FABP7) has the highest mean differential
overexpression in ccRCC compared to normal kidney. We aimed to investigate the significance of FABP7 in ccRCC.
Methods: Immunohistochemical staining for 40 advanced ccRCC cases was performed to investigate correlation
between clinicopathological parameters and FABP7. They were composed of 40–83 years old cases with 33 male, 22
cases with pT ≥ 3, 19 cases with M1, and 16 cases with grade 3. The effect of gene knockdown was analysed by a cell
viability assay and invasion assay in FABP7-overexpressing cell lines (SKRC7 and SKRC10).
Results: Our immunohistochemical analysis showed that higher FABP7 expression significantly correlated with distant
metastasis and poor cancer-specific survival (CSS; both p < 0.05). Functional suppression of FABP7 significantly inhibited
SKRC10 cell growth (p < 0.05) and resulted in a significant reduction of the invasive potential (p < 0.01), but did not
cause growth inhibition of SKRC7 cells. We found that The Cancer Genome Atlas Research Network (TCGA) database
shows FABP6 and 7 as equally overexpressed in the FABP family. Functional suppression of fatty acid binding protein 6
(FABP6) resulted in significant growth inhibition of SKRC7 cells (p < 0.005).
Conclusions: Functional suppression of FABP7 significantly reduced cell viability and invasive potential in a ccRCC cell
line. FABP7 may play a role in progression in some metastatic ccRCCs. The suppressed function may be compensated
by another FABP family member.
Keywords: Fatty acid binding protein 7, Clear cell renal cell carcinoma, Prognostic marker, Therapeutic target, Fatty
acid binding protein 6
Background
Renal cell carcinoma (RCC) accounts for 3% of all cancer
cases in adults, and it is the 11th most common cancer in
men and the 14th most common in women. Its worldwide
incidence and associated mortality in 2012 were ~ 337,000
new cases and 143,000 deaths [1], both of which have
increased steadily over the years [2, 3].
Clear cell RCC (ccRCC) is the most prevalent patho-
logical subtype of this cancer, accounting for 80% of all
cases. Recent advances in our understanding of the under-
lying genetic events leading to ccRCC have given rise to
treatment modalities targeting the vascular endothelial
growth factor (VEGF) signaling axis and its related path-
ways. Although VEGF tyrosine kinase inhibitors (VEGF-T-
KIs) and mammalian target of rapamycin (mTOR)
inhibitors significantly extend the progression free survival
of patients with metastatic RCC [4], drug resistance invari-
ably occurs.
Recently, cabozantinib, an inhibitor of tyrosine kinases
including MET, VEGF receptor, and Anexelekto [5], and
nivolumab, an immune check point inhibitor targeting
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programmed cell death 1 on tumor-infiltrating lympho-
cytes [6], became available for clinical use. But it is still
necessary to identify new molecular targets for the treat-
ment of patients with metastatic ccRCC to improve the
treatment outcome. To identify new therapeutic targets, we
performed a transcriptome analysis of ccRCC and normal
kidney samples. Among the up-regulated genes in ccRCC,
we focused on the five most differentially expressed genes;
prolyl hydroxylase 3 (PHD3), fatty acid binding protein 7
(FABP7), carbonic anhydrase IX (CAIX), NADH dehydro-
genase 1 alpha subcomplex, 4-like 2 (NDUFA4L2), and
monocarboxylate transporter 4 (MCT4).
FABP7 is known to be upregulated in brain tissue, and
its function is well studied in glioblastoma cell lines. Zhou
et al. reported that FABP7 is significantly up-regulated in
ccRCC and that the expression of FABP7 positively corre-
lates with advanced clinical stage and poor survival of pa-
tients with ccRCC [7]. Overexpression of FABP7 in RCC
cells enhances cell growth and cell cycle progression,
which activates both extracellular-signal-regulated kinases
(ERK) and signal transducer and activator of transcription
3 (Stat3) signaling.
To the best of our knowledge, this is the first report
about the complementary role of fatty acid binding pro-
tein 6 (FABP6) for FABP7 in ccRCC.
Methods
Transcriptome analysis
Total RNA was extracted from 60 ccRCC samples (49 cases
without metastasis, and 11 cases with synchronous metasta-
sis at nephrectomy), and 20 corresponding normal kidney
samples using the TRIzol Reagent (Invitrogen®). The tumor
samples contained > 70% tumor cells as estimated by
microscopy. Gene expression analysis was performed on the
Genechip Human Gene 1.0 ST Array (Affymetrix®), accord-
ing to the manufacturers’ instructions. The expression
profiles were analyzed using an unsupervised hierarchical
average linkage-clustering algorithm. The analysis was
ethically approved at our institution (Radboud University
Medical Center, Nijmegen).
Antibodies
The following primary antibodies were used: anti-CAIX
monoclonal antibody M75 (HB-11128, ATCC), rabbit
anti-NDUFA4L2 (Proteintech®), anti-PHD3 monoclonal
antibody (Novus Biologicals®), rabbit anti-MCT4 (Milli-
pore®), rabbit anti-FABP7 polyclonal antibody (produced
by a co-author, YO [8]), and a mouse anti-Stat3 mono-
clonal antibody (Abcam®). Primary antibodies were de-
tected using a horseradish peroxidase (HRP)-conjugated
rabbit anti-mouse immunoglobulin antibody) (DAKO®)
and HRP-conjugated swine anti-rabbit immunoglobulin
antibody (DAKO®) (secondary antibodies).
Immunohistochemistry
For immunohsitochemical analysis, we used the slides of
paraffin-embedded ccRCC and normal kidney samples
extracted from the same cases used in our transcriptome
analysis.
Slides of paraffin-embedded ccRCC samples were deparaf-
finized in xylene, followed by incubation in a graded series
of ethanol (100, 70 and 50%) and re-hydration in PBS. The
slides were immersed in 3% H2O2 for 30min at room
temperature to block endogenous peroxidase activity. After
a PBS wash, the slides were immersed in 10mM citrate buf-
fer (pH 6.0) and heated in a microwave oven for 10min at
100 °C. After cooling to room temperature, the slides were
blocked in 20% normal goat serum for 10min. The tissue
slices were then incubated with the mouse anti-CAIX
monoclonal M75 antibody (1600 dilution), rabbit anti-NDU-
FA4L2 polyclonal antibody (12,000 dilution), mouse
anti-PHD3 monoclonal antibody (1200 dilution), rabbit
anti-MCT4 polyclonal antibody (1200), or the rabbit
anti-FABP7 polyclonal antibody (11000) for 90min at room
temperature, washed in PBS, and then incubated with the
appropriate secondary antibody for 1 h at room temperature
(1100 dilution). After washing with PBS, the slides were
incubated in a PowerVision DAB solution (40 μl of
Solution A + 40 μl of Solution B + 5 μl of Tween 20
brought up to 1 ml with PBS, ImmunoLogic®) for 10
min at room temperature, washed again in tap water,
counterstained with hematoxylin, and mounted in Per-
mount (Fisher Scientific®).
Patients’ characteristics in the cases analyzed by FABP7
immunohistochemical staining
We retrospectively reviewed the clinical data of 40
patients with metastatic ccRCC who had undergone
nephrectomy, followed by systemic therapy using either
a cytokine, VEGF-TKIs, or mTOR inhibitors in Yama-
guchi University Hospital. The analysis was ethically
approved at our institution (Yamaguchi University
Hospital).
Evaluation of FABP7 expression status in ccRCC
specimens
We scored the FABP7 staining index based on the staining
intensity (Fig. 2a, low: 1, intermediate: 2, high: 3, and
nuclear staining: 4 points) and the number of the cells as
calculated by the formula: (staining intensity 1, 2, 3, or
4) × cell counts per 500 cells in each sample of ccRCC
specimen. The mean value of the index was 11 in all the
cases analyzed. We defined the case with more than mean
value of the index as high FABP7 expression case, and also
defined the case with less than mean value of the index as
low FABP7 expression case.
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RNA extraction and real-time quantitative RT-PCR
Total RNA was extracted from the cultured cells using the
TRIzol Reagent (Invitrogen®). RNA was used for reverse
transcription with SuperScript II RNase Hˉ Reverse Tran-
scriptase (Invitrogen®). The cDNA synthesis was per-
formed using 2 μg of RNA with a mix of reverse
transcriptase, 5× first-strand buffer, DTT, dNTPs, and ran-
dom hexamers.
qRT-PCR was run using a LightCycler 480 Real-Time
PCR System (Roche®). The SYBR Green method was
used to measure hypoxanthine phosphoribosyltransferase
1 (HPRT), CAIX, MCT4, FABP7 and FABP6 mRNA ex-
pression and the TaqMan method to measure HPRT,
PHD3-, and NDUFA4L2 mRNA expression levels. The
primer sequences were as follows:
HPRT
Forward primer sequence: 5’CTCAACTTTAACTGGA
AAGAATGTC3’
Reverse primer sequence: 5’TCCTTTTCACCAGC
AAGCT3’
Probe sequence: 5’TTGCTTTCCTTGGTCAGGCAGT
ATAATC3’
CAIX
Forward primer sequence: 5’TAAGCAGCTCCACACC
CTCT3’
Reverse primer sequence: 5’TCTCATCTGCACAAGG
AACG3’
MCT4
Forward primer sequence: 5’GCACCCACAAGT TCT
CCAGT3’
Reverse primer sequence: 5’CAAAATCAGGGAGGAG
GTGA3’
PHD3
Forward primer sequence: 5’GAATTGGGATGCCAAG
CTACA3’
Reverse primer sequence: 5’TGACCAGAAGAACA
GGAGTCTGTC3’
Probe sequence: 5’ATGGGCTCCACATCTGCTATGA
ATGATTTC3’
NDUFA4L2
Forward primer sequence: 5’GACGTCTGCTGGGA
CAGAAAG3’
Reverse primer sequence: 5’AGTGGAAACTGCAAGG
AACTTGTA3’
Probe sequence: 5’CCGGAGCCCTGGAACCGC3’
FABP7
Forward primer sequence: 5’CTCAGCACATTCAAGA
ACACG3’
Reverse primer sequence: 5’CCATCCAGGCTAACAA
CAGAC3’
FABP6
Forward primer sequence: 5’ACTACTCCGGGGGCCA
CACCAT3’
Reverse primer sequence: 5’GTCTCTTGCTCACGCG
CTCATAGG3’
HPRT mRNA expression served as an internal control.
All the measurements were repeated at least twice to
confirm reproducibility. The expression of the target
mRNA was quantified relative to that of the HPRT
mRNA and untreated controls were used as a reference
according to the model described by Pfaffl [9].
Cell culture
Human ccRCC-derived cell lines (SKRC1, SKRC7,
SKRC10, SKRC12, SKRC17, SKRC59, and CaKi1) were
cultured in the RPMI 1640 medium supplemented with
10% of fetal calf serum and ʟ-glutamate (Gibco®) in a
humidified atmosphere containing 5% of CO2 at 37 °C.
Western blot analysis
Protein expression levels were determined by western
blot analysis. In brief, cells were lysed in a buffer consist-
ing of 20 mM Tris-HCl (pH 7.5), 150 mmol/l NaCl, 0.1%
SDS, 5 mmol/l EDTA, 1% of Triton X-100 (Sigma-Al-
drich®), and 1 tablet of a protease inhibitor cocktail
(cOmplete Mini, Roche®) per 10 mL of the buffer. The
lysates were centrifuged at 13,200 rpm for 15 min at 4 °
C, and the supernatants were collected to determine
protein concentration using the BSA protein assay re-
agent. Total protein (10 or 20 μg) was separated by
SDS-PAGE in a 10% gel and transferred to a filter using
a semidry blotter. After blocking with 1% skimmed milk
powder dissolved in PBS, the blots were incubated with
the appropriate primary and secondary antibodies: the
rabbit anti-FABP7 polyclonal antibody (1,5000) and
mouse anti-Stat3 monoclonal antibody (110000). Detec-
tion was performed using the Amersham ECL Plus
Western Blotting Detection Reagents kit (Amersham®),
and protein expression levels were quantified in the Ima-
geJ software (NIH, USA).
The knockdown with small interfering RNA (siRNA)
A commercially available mixture of 4 single-stranded
19-bp siRNAs (ON-TARGETplus SMARTpool, Invitro-
gen®) was used to transfect SKRC7 and SKRC10 cells
according to the manufacturer’s instructions. The se-
quences of the siRNAs were 5’CAACGGUAAUUAUC
AGUCA3’, 5’GUCAGAACUUUGAUGAGUA3’, 5’GAAC
ACGGAGAUUAGUUUC3’, and 5’GAUGAUAGAAAC
UGUAAGU3’ for FABP7, 5’UCGGAGGCGUGACCUAU
GA3’, 5’CCUCAGAGAUCGUGGGUGA3’, 5’GUGAGAA
GAAUUAUGAUGA3’, and 5’GCAAGGAAAGCAACAU
ACA3’ for FABP6.
The final concentration of siRNA for transfection was 33
nmol/L. A scrambled siRNA served as a negative control
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(Invitrogen®). Transfection was carried out using Lipofecta-
mine 2000 (Invitrogen®).
Cell viability assay
Cell viability was tested by a 3-(4,5-dimethylthiazo-
l-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
SKRC7 and SKRC10 cells transfected with scrambled
siRNA, FABP7 siRNA, or FABP6 siRNA were seeded in
triplicate in 96-well plates at 4000 cells per well and
cultured at 37 °C and 5% CO2 for up to 7 days. On the
day of measurement, 30 μL of MTT Thiazolyl Blue (5
mg/mL: Sigma-Aldrich®) was added into each well, and
the cells were incubated for an additional 4 h. Subse-
quently, 100 μL of DMSO was added, and the plate was
shaken for 5 min at room temperature to dissolve
the formazan crystals. Finally, optical density (OD)
at 595 nm was measured (3550 Microplate Reader,
Bio-rad®).
Table 1 Highly mRNA overexpression in ccRCC compared to normal kideny
Gene Symbol Ref Seq LSMean (NK) LSMean (RCC) Fold-Change (RCC/NK)
FABP7 NM_001446 3.20163 9.76575 94.6231
NDUFA4L2 NM_020142 5.26123 10.5235 38.3803
CP NM_000096 5.94544 10.8426 29.7987
HIG2 NM_013332 4.40522 9.16447 27.0818
ANGPTL4 NM_139314 3.92434 8.28295 20.5151
CA9 NM_001216 4.36817 8.66135 19.6054
ANGPT2 NM_001147 4.81109 8.97052 17.8695
EGLN3 NM_022073 5.49587 9.45616 15.5656
C3 NM_000064 7.32719 11.2612 15.2848
AHNAK2 NM_138420 3.73036 7.61734 14.7944
NETO2 NM_018092 4.68377 8.51052 14.1895
ENO2 NM_001975 4.74515 8.47351 13.254
NNMT NM_006169 5.63127 9.29046 12.6335
LOX NM_002317 6.23912 9.89302 12.5873
CYP2J2 NM_000775 4.48354 8.08306 12.1217
TNFAIP6 NM_007115 3.21484 6.78895 11.9101
PNMA2 NM_007257 4.42318 7.86148 10.8401
RRM2 NM_001034 3.95228 7.36327 10.6368
VWF NM_000552 5.54317 8.90743 10.2978
CXCL10 NM_001565 4.73448 8.09726 10.2872
NPTX2 NM_002523 4.07029 7.42967 10.263
TMEM45A NM_018004 3.75004 7.07615 10.029
CXCL11 NM_005409 3.39841 6.6673 9.63905
SLC16A3 NM_001042422 4.92069 8.18727 9.62364
IGFBP3 NM_001013398 7.18489 10.4391 9.54115
ENPP3 NM_005021 6.77557 9.96963 9.15181
DNAH11 NM_003777 3.34526 6.53492 9.12395
SCD NM_005063 6.71436 9.89784 9.08496
CXCL9 NM_002416 4.06238 7.23311 9.00504
FCGR3A NM_000569 4.98514 8.13677 8.88659
BHLHE41 NM_030762 5.29995 8.40999 8.63406
HK2 NM_000189 4.30467 7.39848 8.53744
PCSK6 NM_002570 4.33254 7.34167 8.05077
GBP5 NM_052942 4.17666 7.1851 8.04697
ESM1 NM_007036 6.14498 9.1468 8.0101
PDK1 NM_002610 6.19808 9.19637 7.99055
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Cell invasion assay
This assay was conducted using a BD BioCoat Matrigel
Invasion Chamber (BD-Biosciences®).
SKRC10 cells were harvested 48 h after transfection at
37 °C. The transfected cells were re-suspended in serum-
free Dulbecco’s modified Eagle’s medium and then added
to the upper chamber at a density of 2 × 105 cells/well.
After 24 h of incubation at 37 °C, cells migrating through
the membrane were stained. The results are expressed
as invading cells quantified at OD 560 nm.
Statistical analysis
Student’s t test was used for statistical analysis using
commercially available software (JMP version 4, SAS). A
different with a p-value less than 0.05 was considered
significant.
Results
Transcriptome analysis
This analysis revealed numerous genes that were over-
expressed in ccRCC samples compared to normal kidney
tissues (Table 1). Five genes (PHD3, FABP7, CAIX, NDU-
FA4L2, and MCT4) were expressed approximately 10-fold
higher in ccRCC specimens compared to normal kidney
samples (Fig. 1a). Higher expression levels of these genes
were also observed in The Cancer Genome Atlas Research
Network (TCGA) database. The mRNA expression levels
of PHD3, CAIX, NDUFA4L2, and MCT4 were equally
high in most ccRCC samples, and did not depend on can-
cer progression. In contrast, the levels of FABP7 mRNA
varied. Among the overexpressed genes, FABP7 had the
highest mean expression level at the mRNA level, and the
expression levels varied depending on the ccRCC cases.
Fig. 1 Highly overexpressed molecules in ccRCC samples. a Highly upregulated genes based on the transcriptome analysis. The figure shows
fold- changes of differential expression for highly upregulated genes. ●: normal kidney, ■: RCC that never metastasized, ▴: RCC that metastasized
after nephrectomy, ×: RCC with metastasis prior to nephrectomy, ✳: metastatic RCC.Vertical and horizontal axes indicate fold changes in mRNA
expression and numbers of cases, respectively. b Immunohistochemical staining for PHD3, CAIX, NDUFA4L2, and MCT4. Representative cases of
immunohistochemical staining in paraffin-imbedded tissues slices (magnification: × 400)
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Immunohistochemistry
Immunohistochemical staining was used to determine
whether the differential mRNA expression of these
genes was reflected in differential protein expression in
the ccRCC and normal kidney samples. Homogenous
staining was observed in ccRCC samples for PHD3,
CAIX, NDUFA4L2, and MCT4, while the staining level
of FABP7 varied among the cases. Representative cases
of differential immunohistochemical staining for PHD3,
CAIX, NDUFA4L2, and MCT4 in ccRCC and normal
kidney samples are shown in Fig. 1b. CAIX was not
expressed in normal kidneys. PHD3 expression was
weak in all epithelial cells of the kidney, whereas
MCT4 and NDUFA4L2 expression was restricted to
the distal tubuli.
FABP7 immunohistochemical staining as a prognostic
marker
We retrospectively reviewed the clinical data of 40 patients
with metastatic ccRCC who had undergone nephrectomy,
followed by systemic therapy using either a cytokine,
VEGF-TKIs, or mTOR inhibitors in Yamaguchi University
Hospital. The analysis was ethically approved at our institu-
tion (Yamaguchi University Hospital).
To evaluate the efficacy of FABP7 as a biomarker, we
retrospectively reviewed the clinical data of 40 patients
with metastatic ccRCC who had undergone nephrec-
tomy, followed by systemic therapy using either a
cytokine, VEGF-TKIs, or mTOR inhibitors in Yamagu-
chi University Hospital. The expression pattern of
FABP7 was consistent in the cytoplasm, while nuclear
expression varied. The expression of FABP7 was fre-
quently observed in the peripheral lesion of the tumor
with viable cancer cell, while was not in the central le-
sion with necrotic tissue. The expression level of
FABP7 depended on the cases in agreement with tran-
scriptome analysis. Distribution status of the FABP7
staining index among the 40 ccRCC cases is shown in
Fig. 2b. We classified the cases into those with higher
or lower expression of FABP7 based on the FABP7
staining index.
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Fig. 2 FABP7 expression in ccRCC samples. a Immunohistochemical staining for FABP7. Different immunohistochemical staining intensities in
paraffin-imbedded tissues slices (magnification: × 400) are shown. Vertical axis shows the FABP7 staining index. Eleven is the mean value of the
index in 40 cases. The horizontal axis shows the number of cases. b Distribution of FABP7 expression in clinical cases. Vertical axes show the
FABP7 staining index. Eleven is the mean value of the index in 40 cases. The horizontal axis shows the number of the cases. ●: Male case, ●:
Female case. c Correlation between FABP7 expression and cancer-specific survival. Vertical axis shows the cancer-specific survival rate. The
horizontal axis shows the days after treatment
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Table 2 depicts the relation of patient characteristics
to FABP7 expression. The cases with higher FABP7
expression significantly correlated with distant metasta-
sis and corrected calcium level (both, p < 0.05). Then we
analysed the role of FABP7 expression as a prognostic
marker. In our cohort, other known prognostic factors
(pT stage, grade, Hb, neutrophil, LDH, CRP, Na, cor-
rected calcium) could not show significant correlation
with cancer-specific survival (CSS), while FABP7 could
be a prognostic marker (Fig. 2c). Cases with higher
FABP7 expression significantly correlated with poor CSS
as compared to those with lower expression (p < 0.05).
Functional effects of a FABP7 knockdown
The mRNA and protein expression levels of FABP7 were
evaluated in 7 ccRCC-derived cell lines: SKRC1, SKRC7,
SKRC10, SKRC12, SKRC17, SKRC59, and Caki1. The
mRNA levels are shown in Fig. 3a. SKRC1, SKRC7, and
SKRC10 showed higher expression levels of FABP7 com-
pared to the other cell lines.
We transfected FABP7- siRNA into SKRC10 cells to
knock down the expression of FABP7. This transfection re-
sulted in a > 90% reduction of mRNA expression for 7 days
as compared to scramble transfection (Fig. 3b), and the pro-
tein level was also reduced (Fig. 3c). Interestingly, FABP7
knockdown reduced the expression of Stat3 (Fig. 3c).
We evaluated the effect of the FABP7 knockdown on
SKRC10 cells by the MTT assay. Functional suppression
of FABP7 resulted in significant growth inhibition of
SKRC10 cells at 7 days after transfection (p < 0.05,
Fig. 4a). A Matrigel invasion assay indicated a significant
reduction in the invasive potential by the functional
suppression of FABP7 (p < 0.01, Fig. 4b).
FABP6 expression
Although higher expression of FABP7 was observed in
SKRC7 cells than in SKRC10 cells, suppression of
FABP7 in SKRC7 cells did not affect the cell viability
as shown in Fig. 5b. Therefore, we analysed relative
mRNA expression of FABP6, a member of the FABP
family, in ccRCC cell lines and showed high expres-
sion of FABP6 mRNA in SKRC7 cells, while SKRC10
cells had low expression of FABP6 mRNA (Fig. 5a).
We evaluated the effect of the FABP6 knockdown on
SKRC7 cells by the MTT assay. Functional suppression
of FABP6 resulted in significant growth inhibition of
SKRC10 cells at 7 days after transfection (p < 0.05, Fig.
5b), while combined knock down of FABP7 and FABP6
did not inhibit the cell growth more than knock down of
FABP6 alone. In SKRC7 cells, FABP6 seemed to com-
pensate the role of FABP7 in cell proliferation.
Discussion
Most cancer cells undergo a metabolic shift from electron
transport chain to glycolysis in producing energy, which
resulted in synthesizing proteins and lipids. Increased
Table 2 Correlation between clinicopathological characteristics and FABP7 expression
FABP7 index
Characteristics Criteria High (> 11) High (< 11) P value
Age (years) High (≥65) 9 12 0.5273
Low (< 65) 11 8
Gender Male 15 18 0.4075
Female 5 2
Grade High (3) 10 6 0.3332
Low (1 or 2) 10 13
pT stage High (3) 11 11 1
Low (1 or 2) 8 9
N stage + 1 0 1
– 18 19
M stage + 13 6 < 0.05
– 4 11
Natrium (mEq/l) High (> 142) 1 4 0.3398
Low (≤142) 18 15
Albumin (g/dl) High (≥3.7) 8 12 0.5027
Low (< 3.7) 9 7
Corrected Calcium (mg/dl) High (≥10) 9 3 < 0.05
Low (< 10) 8 15
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Fig. 4 Effect of FABP7 knockdown in a ccRCC cell line. a The cell viability assay after the FABP7 knockdown. Proliferating SKRC10 cells after the
knockdown of FABP7 expression were assessed by an MTT assay. Vertical bars indicate the value of optical density (OD) of the cells at 595 nm.
*p < 0.05. b Invasion assay after the FABP7 knockdown. Invading SKRC10 cells after the knockdown of FABP7 were analyzed by the Matrigel
Invasion assay. Vertical axis indicates the value of optical density (OD) of the cells at 560 nm. **p < 0.01
Nagao et al. BMC Cancer         (2018) 18:1114 Page 8 of 11
glucose uptake and the accumulation of lactate are com-
mon features of cancer cells even under normoxic condi-
tions named as the Warburg effect [10, 11]. HIF-1α
promotes angiogenesis by inducing VEGF [12], which
upregulates the transcription of various glycolytic genes to
mediate a metabolic shift that shunts glucose metabolites
away from mitochondria [13]. In ccRCC, hypoxia-indu-
cible factor- 1α (HIF-1α) is overexpressed due to func-
tional loss of the von Hippel-Lindau (VHL) protein.
Recent studies showed that the Warburg Effect in cancer
cells can be targeted by inhibition of glucose transporter
1, [14], or conversion of lactate to pyruvate by lactate de-
hydrogenase A (LDH-A) [15]. HIF-1a was reported to
regulate the expression of fatty acid synthase (FASN) [16],
which facilitate fatty acid synthesis and lipid storage [17].
Recently, several FASN inhibitors were reported to show
antitumor effect against breast [18], ovarian [19], and
prostate cancers [20] in preclinical models.
Based on our transcriptome analysis, we focused on
the five most differentially expressed genes: PHD3,
FABP7, CAIX, NDUFA4L2, and MCT4. All the genes
have been regarded as working downstream of HIF in
relation to hypoxia, metabolism, and pH regulation in
cancer, which are supposed to induce the Warburg effect
[21]. Our results are in good agreement with a meta-
analysis of 5 ccRCC expression datasets available in
Oncomine [22], in which NDUFA4L2, PHD3, CAIX, and
MCT4 showed the 1st, 2nd, 7th, and 11th highest ex-
pression level, respectively. In addition, our data indicate
that these genes are equally highly expressed in tumor
samples of non-metastatic and metastatic cases, which
revealed that these genes are stably over-expressed in
the vast majority of ccRCCs compared to normal kidney
tissue regardless of the metastatic potential or tumor
stage. In contrast, heterogeneous distribution of mRNA
expression of FABP7 with a higher average value leads
a
b
-10.00
-5.00
0.00
5.00
10.00
15.00
20.00
25.00
30.00
35.00
F
A
B
P
6/
H
P
R
T
0.000
0.100
0.200
0.300
0.400
0.500
0.600
0.700
0.800
0.900
1 3 5 7
P
ro
lif
er
at
io
n
(O
D
 5
95
nm
)
Time (days)
SKRC7/Scr-siRNA SKRC7/FABP7-siRNA
SKRC7/FABP6-siRNA SKRC7/FABP7- and FABP6-siRNA
***
SKRC1        SKRC7       SKRC10       SKRC12      SKRC17       SKRC59        Caki1
Fig. 5 Effect of FABP7 knockdown in ccRCC cell lines. a Relative mRNA expression of FABP6 in ccRCC cell lines. Relative mRNA expression levels in
ccRCC cell lines are shown. Vertical axis indicates the ratio of CP values (FABP6/HPRT). b Cell viability assay after FABP7 or/and FABP6 knockdown.
Proliferating SKRC7 cells after the knockdown of FABP7 or/and FABP6 were analyzed by the MTT assay. Vertical axis indicates the value of optical
density (OD) of the cells at 560 nm. **p < 0.05
Nagao et al. BMC Cancer         (2018) 18:1114 Page 9 of 11
to the hypothesis that FABP7 may be involved in cancer
progression in ccRCC.
FABP7 is a member of the FABP family, which is known
to have family members 1 to 7 in cancer tissue. Bensaad et
al. showed that a knockdown of FABP3, FABP7, or
Adipophilin impaired lipid droplet formation under hyp-
oxic conditions in glioblastoma and breast cancer cell lines
[23]. They supposed that inhibition of lipid storage may re-
duce the ability in protecting the cancer cells from toxicity
by reactive oxygen and decrease the survival of the cancer
cells under the condition of hypoxia-reoxygenation. Liu et
al. reported that FABP7 is significantly up-regulated in
triple-negative breast cancer and that the high expression
level of FABP7 is associated with poor prognosis [24]. They
also showed that depletion of FABP7 significantly reduced
the growth rate of cancer cells, which leads to sensitize the
growth inhibition by omega-3 docosahexaenoic acid
(DHA). We also added DHA to the FABP7- knockdown
SKRC10 cells in a cell viability assay, but growth inhibition
was not affected (data not shown). In FABP7-overexpress-
ing RCC cells, Zou et al. showed that overexpression of
FABP7 in RCC cells promotes cell growth by the activation
of ERK and Stat3 signaling pathways [7]. In our study, it
was also confirmed that the knockdown of FABP7 reduced
Stat3 expression, which may result in growth inhibition and
reduction of the invasive potential.
On the other hand, Takaoka et al. reported that the
levels of FABP7 expressed in a ccRCC cell line
(TUHR14TKB) and their doubling times decreased dur-
ing passage. They also reported that the proliferation
and the cell migration property of the cell line decreased
when FABP7 was overexpressed. They concluded that
the difference in FABP7 function between RCC cell lines
suggests that FABP7 affects cell proliferation depending
on cell phenotype [25].
Although FABP6 mRNA was not highly differentially
expressed in our transcriptome analysis, it does have
high differential expression in ccRCC tissues compared
to normal tissue according to TCGA database (Table 3)
[26]. The expression level of FABP6 mRNA is reported
to be comparable to that of FABP7 mRNA, while there
are no reports showing prognostic significance of FABP6
in ccRCC. Ohmachi et al. reported that the expression
of FABP6 is higher in primary colorectal cancers than in
normal epithelium, but is decreased in lymph node me-
tastases. They supposed that FABP6 may play an import-
ant role in early carcinogenesis [27]. Our study showed
that FABP6 can complement FABP7 in a cell
type-dependent manner and indicates that a knockdown
of FABP7 and/or FABP6 can reduce viability and inva-
sive potential of ccRCC cells. Specific inhibition of fatty
acid binding proteins may be a novel strategy against
ccRCC.
Conclusions
Functional suppression of FABP7 significantly reduced
cell viability and invasive potential in a ccRCC cell line.
FABP7 may play a role in progression in some metastatic
ccRCCs. The suppressed function may be compensated
by another FABP family member.
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FABP5 938,428 236,739 3.96
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